BRCA2, HER2, P53 and Ki67). About 5%-10% of breast cancer cases are supposed to be hereditary 1 and individuals with these mutations have significantly higher susceptibility to developing breast cancer.
Recent genome-wide association (GWA) studies have reported that genetics variants in a region located on chromosome 9p21.3 are associated with multiple cancers 2-5 such as ovarian cancer, acute lymphoblastic leukemia, glioma, malignant melanoma, breast cancer, pancreatic cancer, nasopharyngeal neoplasm, and glaucoma.
5,6
The chromosome 9p21.3 region adjacent to the loci encoding the cyclin-dependent kinase inhibitors CDKN2A (ENSG00000147889)
and CDKN2B (ENSG00000147883) is an important susceptibility locus for various diseases with a complex genetic background. INK4b, which inhibit cyclin-dependent kinase 4 (CDK4) and cyclindependent kinase 5 (CDK5), respectively. CDK4 and CDK5 play an important role in different cell function and regeneration. 6 Several genetic polymorphisms have been suggested in the upstream of CDKN2A/B, which might influence the expression of these genes and thereby cell cycle. 11 Therefore, the aim of this study was to examine the association of CDKN2A/B rs10811661 polymorphism with breast cancer. 
| MATERIALS AND METHODS

| Patient samples
| DNA extraction and genotyping
Genomic DNAs were extracted from peripheral blood leukocytes using QIAamp ® DNA Mini-Kit (Qiagen, San Diego, CA, USA) according to the manufacturer's protocol. The concentration and purity of DNA samples were determined using the NanoDrop ® -1000-Detector (NanoDrop-Technologies, Wilmington, DE, USA).
Genotype analysis of CDKN2A/B-rs10811661 polymorphism was carried out using Taqman ® -probes-based assay; PCR reactions were carried out in 12.5 μL total volume, using 20 ng of DNA in 
| RESULTS
| Association of the genetic variant with clinical characteristics of population
In order to explore whether there was an association between CDKN2A/2B Rs10811661 (C/T) polymorphism and breast cancer, genotyping was performed in all the subjects using DNA extracted from peripheral blood samples. Genotyping was successfully performed in the all DNA samples and no discrepancies were found in the samples analyzed in duplicate. 
| Association of the genetic variant with poor prognosis of patients
The distribution of different genotypes (CC, CT, and TT) of CDKN2A/B rs10811661 polymorphism in breast cancer patients and healthy subjects is presented in Table 2 . The risk T allele frequency was 85%, and the frequencies of CC, CT, and TT genotypes were 0.03, 22.9, and 74%, respectively, in total population. Patients with breast cancer had a significantly higher frequency of TT genotype (P<.001) than control group (Table 2) . Moreover, the logistic regression analysis under recessive genetic model showed that TT carriers had a higher risk of breast cancer (OR=4.9, 95%CI: 1.9-12, P=.001), with respect to CC/ CT genotypes, after adjusted for potential confounders, age, BMI, and family history. However, no statistically significant association was detected for the association of this marker in other genetic models (eg, additive and dominant models). T A B L E 2 Association between the genetic polymorphism in CDKN2A/B rs10811661 with breast cancer 14 However, the potential mechanisms underlying the role of ANRIL in breast carcinogenesis still remained to be elucidated. 16 Dębniak et al., 3 suggested the value of CDKN2A as a breast cancer susceptibility gene. They showed that the CDKN2A A148T variant might be contributed to early-onset breast cancer in Poland. 17 In line with these studies, Antoniou and colleagues found the association of the rs1011970, near CDKN2A/CDKN2B, with increased breast cancer risk. 18 Another large-scale case-control study conducted by Driver et al., 19 examined several polymorphisms within 13 genes involved in the cell cycle pathway with breast cancer risk. They illustrated a significant relationship between four genetics variants within the region of CDKN2A/2B and breast cancer risk.
| DISCUSSION
In aggregate, our finding revealed for the first time a correlation between the genetic polymorphism, rs10811661, in CDKN2A/B gene and breast cancer. In particular, our data showed that this genetic marker was related with tumor grade and tumor size, although further studies in a larger population are needed to explore it values as a potential biomarker in risk stratification or prediction a chance of developing breast cancer.
